N004 (HIVCORE 004)

Phase:
I/IIA
Status:
Completed
Strategies:
DNA, Viral Vector - Pox, Viral Vector-Adeno
Candidates:
Ad35-GRIN, MVA.HIVconsv, pSG2.HIVconsvDNA
Countries:
Kenya
Volunteers:
72
Partners:
IAVI; University of Oxford; European and Developing Countries Clinical Trials Partnership (EDCTP); Karolinska Institutet; University of Nairobi Ichor Medical Systems Incorporated
 
A Phase I/IIa Clinical Trial of HIV-1 Vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in Combined Regimens in Healthy HIV-1/2-negative Adults in Nairobi
 
The study is part of a long-term aim to develop an effective HIV-1 vaccine and will evaluate safety and immunogenicity of vaccines focusing T cell responses on  the conserved region of the HIV-1 proteome. The vaccines used are pSG2.HIVconsv DNA (D), MVA.HIVconsv (M) and Ad35-GRIN (A), delivered in regimens AM, DDDAM and DeDeDeAM, where e indicates electroporation. ClinicalTrials.gov Identifier: NCT02099994